

REMARKS

The present application is directed to endostatin proteins, which are useful for the inhibition of angiogenesis and the treatment of angiogenesis-dependent diseases such as cancer. As used in the present specification, the term "isolated" refers to material which is free from at least some of the constituents within which it is naturally associated.

New Claims 34-51 have been added, however, no new matter is contained therein. Support for the new Claims 34-51 can be found throughout the specifications of U.S. Patent Application Serial No. 09/154,302 and U.S. Patent No. 5,854,205. Additionally, Applicants respectfully request the Examiner to review the co-pending patent applications listed on attached Appendix A. The listed patent applications are pending patent applications filed by The Children's Medical Center Corporation that disclose endostatin proteins, nucleotide fragments encoding endostatin proteins, methods of detecting endostatin proteins, and methods of using the proteins and nucleotides. Applicants have cited the co-pending applications on a separate document, as opposed to form PTO-1449, in accordance with MPEP §609 (D) so as to avoid the serial numbers of the listed applications being published on the patent resulting from the present application. Applicants do not waive the confidentiality of the listed patent applications. Applicants request that the Examiner review and initial each application listed in attached Appendix A and return an initialed copy of Appendix A to Applicants' representative.

No additional fees are believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-1215. In light of the amendments and the above remarks, Applicants are of the opinion that the application is now in condition for allowance. Such action is respectfully requested.

If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 949-2400 is respectfully solicited.

Respectfully submitted,

JONES & ASKEW, L.L.P.



By: Lisa C. Elsevier
Reg. No. P44,669

JONES & ASKEW, L.L.P.
2400 Monarch Tower
3424 Peachtree Road, N.E.
Atlanta, Georgia 30326
Attorney Docket No. 05213-0640